Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
POLA1 inhibitor
- Development stage
- Preclinical
- Lead developer
- Cumulus Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The POLA1 inhibitor is a preclinical-stage small molecule therapeutic being developed by Cumulus Oncology in collaboration with the Lead Discovery Center (LDC) in Germany. It targets the DNA polymerase alpha catalytic subunit (POLA1), which is the enzyme responsible for the initiation of DNA replication by synthesizing RNA-DNA primers on both the leading and lagging strands. By inhibiting POLA1, the drug interferes with the DNA replication process, leading to replication stress and potential cell death in rapidly dividing cancer cells. The program is currently in the discovery to lead optimization phase, focusing on oncology indications with high unmet medical needs.
- Other names
- POLA1 inhibitorPOLA-1 inhibitorPOLA 1 inhibitor
02
Targets
POLA1 (DNA polymerase alpha)
Beyond the preview
Go deeper on POLA1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POLA1 inhibitor.